Retisert: Withdrawal of the marketing authorisation application


On 16 July 2007, Bausch & Lomb Ireland officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for RETISERT, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. RETISERT was designated an orphan medicinal product on 7 March 2005.

  • List item

    Questions and answers on the withdrawal of the marketing application for Retisert (PDF/35.19 KB)

    First published: 03/09/2007
    Last updated: 03/09/2007

  • Key facts

    Product number
    Active substance
    • Fluocinolone acetonide
    Date of withdrawal
    Company making the application
    Bausch Lomb Ireland
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating
    1 rating